Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Receivables: 2015-2025

Historic Receivables for Editas Medicine (EDIT) over the last 10 years, with Sep 2025 value amounting to $8.1 million.

  • Editas Medicine's Receivables rose 6352.38% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 136.01%. This contributed to the annual value of $16.3 million for FY2024, which is 59.67% up from last year.
  • As of Q3 2025, Editas Medicine's Receivables stood at $8.1 million, which was up 1,282.65% from $588,000 recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Receivables peaked at $16.3 million during Q4 2024, and registered a low of $120,000 during Q3 2022.
  • Over the past 3 years, Editas Medicine's median Receivables value was $588,000 (recorded in 2025), while the average stood at $3.7 million.
  • As far as peak fluctuations go, Editas Medicine's Receivables crashed by 95.59% in 2021, and later spiked by 6,352.38% in 2025.
  • Quarterly analysis of 5 years shows Editas Medicine's Receivables stood at $267,000 in 2021, then soared by 1,826.97% to $5.1 million in 2022, then soared by 98.00% to $10.2 million in 2023, then surged by 59.67% to $16.3 million in 2024, then surged by 6,352.38% to $8.1 million in 2025.
  • Its Receivables stands at $8.1 million for Q3 2025, versus $588,000 for Q2 2025 and $510,000 for Q1 2025.